Immunocore Holdings plc
IMCR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001671927
No open-market purchases or sales by Immunocore Holdings plc insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $1.65B in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Immunocore Holdings plc changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 45 | 47 | +2 |
| Shares | 14.4M | 16.7M | +2.27M (+15.8%) |
| Value | $561.1M | $617.4M | +$56.2M (+10.0%) |
New holders (7)
Institutions that held Immunocore Holdings plc at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| First Manhattan Co | 197,999 | $7.34M | 0.03% |
| Pier Capital, LLC | 78,514 | $2.91M | 0.30% |
| Pura Vida Investments, LLC | 50,000 | $1.85M | 0.14% |
| State Street Corp | 6,200 | $230.0K | 0.00% |
| Geneos Wealth Management Inc. | 4,250 | $163.0K | 0.01% |
| Sphera Funds Management Ltd. | 4,235 | $157.0K | 0.02% |
| Cubist Systematic Strategies, LLC | 500 | $19.0K | 0.00% |
Sold out (5)
Institutions that held Immunocore Holdings plc at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 360,966 | $14.1M |
| Tybourne Capital Management (HK) Ltd | 138,192 | $5.40M |
| J. Goldman & Co LP | 16,685 | $652.0K |
| Bank of New York Mellon Corp | 12,896 | $504.0K |
| Leonteq Securities AG | 1,000 | $39.0K |